Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with revision 2 of Module III on pharmacovigilance inspections

Agenda of the CAT meeting 9-11 September 2026

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Date of authorisation: 13/07/2011, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Sivextro, tedizolid phosphate, Date of authorisation: 23/03/2015, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Suliqua, insulin glargine,lixisenatide, Date of authorisation: 11/01/2017, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Date of authorisation: 22/01/2007, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Bexsero, meningococcal group B Vaccine (rDNA, component, adsorbed), Date of authorisation: 13/01/2013, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Vislyfa, ranibizumab, Date of authorisation: 15/07/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Lupkynis, voclosporin, Date of authorisation: 15/09/2022, Revision: 8, Status: Authorised